Triprolidine
| 證據等級: L5 | 預測適應症: 7 個 |
目錄
Triprolidine: From Antihistamine (Allergic Symptoms) to Allergic Urticaria
One-Sentence Summary
Triprolidine is a first-generation H1 antihistamine, but its original approved indication and market data are not available in this evidence pack. The TxGNN model predicts it may be effective for Allergic Urticaria, but this direction is currently supported by 0 clinical trials and 0 direct publications — evidence relies entirely on class-level (drug-class) mechanistic reasoning rather than triprolidine-specific data.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no license data in evidence pack) |
| Predicted New Indication | Allergic Urticaria |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L4 (mechanism-level; no direct clinical/literature support for this specific indication) |
| US Market Status | 未上市 (Not marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in structured form. Based on known pharmacology, triprolidine is a first-generation H1-receptor antagonist (antihistamine), and H1-receptor blockade is the established, guideline-recognized (EAACI/GA2LEN) core mechanism for treating histamine-mediated urticaria and pruritus.
The mechanistic rationale connecting triprolidine to allergic urticaria is therefore a class effect argument: H1 antihistamines as a drug class are first-line urticaria therapy, so it is biologically plausible that triprolidine would also be effective. However, this evidence pack contains no clinical trials and no literature specific to triprolidine for allergic urticaria — the supporting logic is entirely mechanistic extrapolation from the drug class, not from triprolidine-specific data. This is the weakest tier of TxGNN-supported hypotheses and should be treated as a research question rather than a repurposing candidate ready for evaluation.
Notably, related literature does exist for a triprolidine derivative (acrivastine) in cold urticaria (see rank #2, PMID 2901993), and for triprolidine combinations (with pseudoephedrine) in a purulent nasopharyngitis trial (rank #4, PMID 6377256) — but neither directly addresses allergic urticaria, and neither constitutes triprolidine-specific efficacy evidence for the top-ranked indication.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for allergic urticaria specifically.
Note: Related class-level evidence exists for other predicted indications in this pack (e.g., PMID 2901993 for cold urticaria using the triprolidine derivative acrivastine), but no literature directly supports the top-ranked allergic urticaria prediction.
US Market Information
No license/authorization records are available in this evidence pack (market status: 未上市 / Not marketed, 0 total licenses).
Safety Considerations
Please refer to the package insert for safety information.
(Note: This evidence pack flags a Blocking data gap — TFDA package insert warnings/contraindications are not yet available, which prevents completion of the S1 safety pre-screen. Key warnings, contraindications, and drug-drug interaction data are currently listed as data gaps and are omitted here per reporting policy.)
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is high, but the evidence level is only L4 and is based purely on drug-class mechanistic reasoning — there is no triprolidine-specific clinical trial or literature evidence for allergic urticaria, and a Blocking data gap (missing TFDA safety/label data) prevents even a baseline safety evaluation.
To proceed, the following is needed:
- TFDA package insert (warnings, contraindications) — currently a Blocking gap
- Confirmed original approved indication(s) and MOA from DrugBank
- Triprolidine-specific clinical or observational evidence in allergic/chronic urticaria (not just class-level or derivative-drug data)
- Market/licensing status confirmation, since the drug currently shows as not marketed in Taiwan
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.